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Exercise-Induced Cardiac Troponin Elevation
Evidence, Mechanisms, and Implications
Rob Shave, PHD,* Aaron Baggish, MD,† Keith George, PHD,‡ Malissa Wood, MD,†
Jurgen Scharhag, MD,§ Gregory Whyte, PHD,‡ David Gaze, PHD,* Paul D. Thompson, MD¶
Middlesex, Liverpool, and London, United Kingdom; Potsdam, Germany; Boston, Massachusetts;
and Hartford, Connecticut
Regular physical exercise is recommended for the primary prevention of cardiovascular disease. Although the
high prevalence of physical inactivity remains a formidable public health issue, participation in exercise pro-
grams and recreational sporting events, such as marathons and triathlons, is on the rise. Although regular exer-
cise training reduces cardiovascular disease risk, recent studies have documented elevations in cardiac troponin
(cTn) consistent with cardiac damage after bouts of exercise in apparently healthy individuals. At present, the
prevalence, mechanism(s), and clinical significance of exercise-induced cTn release remains incompletely under-
stood. This paper will review the biochemistry, prevalence, potential mechanisms, and management of patients
with exercise-induced cTn elevations. (J Am Coll Cardiol 2010;56:169–76) © 2010 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2010.03.037e
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ehe role of exercise in the prevention, management, and
reatment of cardiovascular disease has been well-described
1). Although regular exercise training reduces cardiovascu-
ar disease risk, recent studies have documented elevations
n biomarkers consistent with cardiac damage (i.e., cardiac
roponin [cTn]) after bouts of prolonged exercise in appar-
ntly healthy individuals (2–5).
cTns are highly specific markers of myocardial cell dam-
ge (6) and are central to the diagnosis of acute coronary
yndromes (ACS) (7). cTn elevation is also apparent in
onditions that result in significant cardiac stress in the
bsence of obstructive coronary disease (8). Even minor
levations in cTn confer worse prognosis in patients across
wide spectrum of disease processes (9–11). Accordingly,
ncreased cTn levels after exercise can generate clinical
oncern and subject athletes to unnecessary hospital admis-
ions and invasive procedures (12). Although numerous
tudies have reported the release of cTn after exercise, there
s no consensus regarding the prevalence, mechanisms, and
linical management of exercise-induced cTn release. This
eview will address cTn biochemistry and present potential
echanisms for exercise-induced cTn release. In addition,
e will summarize the available data characterizing
rom the *Brunel University, Uxbridge, Middlesex, United Kingdom; †Division of
ardiology, Massachusetts General Hospital, Boston, Massachusetts; ‡Liverpool
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niversity of Potsdam, Potsdam, Germany; Chemical Pathology, Clinical Blood
ciences, St. Georges Healthcare NHS Trust, Tooting, London, United Kingdom;
nd the ¶Henry Low Heart Center, Hartford Hospital, Hartford, Connecticut.d
Manuscript received September 15, 2009; revised manuscript received February 19,
010, accepted March 9, 2010.xercise-induced cTn release and provide suggestions on the
anagement of patients with cTn elevation after exercise.
roponin Biochemistry and Routine Clinical Use
tructure and function. The myocardial sarcomeric unit
onsists of 7 actin monomers, double-stranded tropomyo-
in, and a troponin complex (6). The troponin complex is
adpole-shaped (Fig. 1) and is composed of 3 subunits:
roponin T (TnT) (37 kDa), which anchors the complex to
he tropomyosin strand of the thin filament; troponin C
TnC) (18 kDa), which binds calcium ions released from
he sacroplasmic reticulum; and troponin I (TnI) (22.5
Da), which inhibits the enzymatic hydrolysis of adenosine
riphosphate that powers muscle contraction. The globular
ead of the troponin complex comprises TnC, TnI, and the
-terminal portion of TnT, whereas the tail comprises the
-terminal portion of TnT. Most (90%) cTn is bound to
ropomyosin on the thin filament of the myofibril, with the
emainder accounted for by a small unbound cytosolic pool
13). Currently, the function of this pool is not known but
ight serve as a reservoir for repair/regeneration of
ropomyosin-bound troponin.
ntogeny and cardiospecificity. Cardiac and skeletal
uscle share a common developmental pathway but origi-
ate from different embryonic precursors (14). Conse-
uently, different forms of TnT and TnI are found in
ardiac and skeletal muscle with cardiac (c) and skeletal (s)
soforms of TnT (cTnT, sTnT) and TnI (cTnI, sTnI) each
ncoded by separate genes. The cTnT and cTnI follow
istinct pathways during fetal development. During fetal
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Exercise and Cardiac Troponins July 13, 2010:169–76muscle development, 3 distinct
TnT protein isoforms (cardiac,
fast twitch skeletal, and slow
twitch skeletal) are expressed si-
multaneously. A fourth isoform,
fetal cTnT, is transiently ex-
pressed (15) but is ultimately ab-
sent in adults (16). Studies have
reported that the cTnT gene is
expressed in low concentrations
in cardiac and skeletal muscle
ntil mid-fetal development, at which point the cTnT gene
s upregulated in cardiac myocytes and suppressed in skeletal
yocytes (17). Conversely, cTnI is not expressed in the
yocardium during fetal development and is only detectable
n adult cardiac tissue (18). In the absence of cTnI, slow
witch sTnI dominates during fetal cardiac development
ntil ultimately replaced by cTnI during the first 9 months
f life (19).
Although skeletal and cTn proteins demonstrate a sig-
ificant degree of amino acid sequence homology, more
han 100 differences exist between the 2 tissue-specific
soforms. With the unique amino acid sequences, monoclo-
al antibodies have been produced against human cTnT and
TnI, respectively. These antibodies form the basis of the
ighly cardiac-specific immunoassay methods available to
etect cTn. The progressive increase in specificity for both
TnT and cTnI assays has been reviewed previously (6).
elease kinetics and routine clinical use. In ACS, cTn is
eleased from the myocardium into the circulation during
he first few hours after the onset of ischemia in a biphasic
anner. A small initial release of cTn is followed by a larger
ustained release with a peak in serum concentration at 12 to
4 h. The initial rise in serum cTn seems to originate from
he cytosolic pool with the later rise attributable to release of
ound cTn (20). Although debated, the initial release of
ytosolic cTn with ischemia might be due to changes in
yocardial membrane permeability, whereas the release of
ound cTn requires proteolytic degradation and cellular
ecrosis (21). The half-life of cTnT in the circulation is 120
in (22); the half-life of cTnI is presently not known.
Troponin testing is an invaluable tool for evaluating
atients with ischemic chest pain or other clinical syn-
romes. The sensitivity and specificity of cTnT and cTnI
or the detection of myocardial injury is superior to older
iomarkers, including lactate dehyrdogenase, creatine ki-
ase, creatine kinase-myocardial band (CK-MB), and myo-
lobin. The cTn measurement is a component of the
niversal definition of acute myocardial infarction (7). The
elease of cTn due to pathologic myocardial damage can be
ivided into 3 mechanistic categories (23). Primary ischemic
ardiac injury describes cTn release from injury caused by a
uptured coronary arterial plaque and coronary occlusion.
econdary ischemic cardiac injury describes myocardial
schemia with myocyte injury in the absence of atheroscle-
Abbreviations
and Acronyms
ACS  acute coronary
syndrome
CK-MB  creatine kinase-
myocardial band
cTn  cardiac troponin
cTnI  cardiac troponin I
cTnT  cardiac troponin Totic plaque rupture and due to increased myocardial oxygenemand that outstrips myocardial oxygen supply. Nonisch-
mic cardiac injury describes cTn release caused by direct
amage to the myocardium, including blunt trauma (24),
enetrating trauma (25), myocarditis (26), or drug and
oxin-induced cardiotoxicity (27). At the present time, the
elease of cTn by healthy individuals after exercise cannot be
xplained by any of these pathophysiologic scenarios.
iomarkers of Myocardial Injury in Exercise
istorical perspective. Early reports of post-exercise ele-
ations in serum concentrations of the myocardial band
soform of creatine kinase (CK-MB) (28) after the comple-
ion of endurance events led to concern that such activities
ould result in cardiac injury. However, elevations in serum
K-MB after prolonged exercise lack specificity for the
etection of cardiomyocyte damage (29). The CK-MB is
ncreased in the skeletal muscle of distance runners (30)
erhaps because of increases in satellite cells, which repair
njured skeletal muscle (31). Therefore, it is likely that
ndividuals with significant exercise training exposure have
elatively high skeletal muscle concentrations of CK-MB,
hich is released during subsequent exercise-induced mus-
le damage. Thus, in the investigation of exercise-induced
ardiac injury, attention shifted from CK-MB to cTn, a
ighly specific marker of cardiac muscle damage, even in the
resence of significant skeletal muscle breakdown (32).
arly generation cTn assays: skeletal protein cross-
eactivity. Immunoassays for the quantification of serum
Tn isoforms (both T and I) were developed in the late
980s and became commercially available in the U.S. and
urope in the mid to late 1990s. The first-generation cTnT
mmunoassay used bovine cTnT as the reference material
nd cross-reacted with human sTnT (33). Therefore, these
Figure 1 Schematic of Cardiac Muscle
Schematic of cardiac muscle showing location of cardiac troponin I (TnI), car-
diac troponin T (TnT), and troponin C (TnC) in relation to actin and tropomyosin.
Figure illustration by Craig Skaggs.
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July 13, 2010:169–76 Exercise and Cardiac Troponinsarly assays could not reliably differentiate TnT of myocar-
ial from skeletal muscle origin, and these early exercise data
hould be viewed with caution (34). The development of
econd- and third-generation cTnT assays, with recombi-
ant human cTnT as the reference, eliminated this prob-
em. More recently, ultra-high-sensitive assays have been
eveloped and are undergoing clinical evaluation (35).
Tn elevation after exercise. Multiple studies have exam-
ned the cTn response to physical exertion, most from
ompetitive athletic events that require a participant to
aintain an elevated cardiac output, heart rate, and systolic
lood pressure for several hours. This sustained increase in
ardiac work stresses the myocardium, which in conjunction
ith the physiologic milieu of prolonged exercise (e.g.,
levations in reactive oxygen species, altered ph, and
ncreased core temperature) could hypothetically damage
ardiomyocytes. Troponin levels from participants in
arathon-distance (4,36 –38) and ultra-distance foot
aces (39,40), triathlons (sequential swimming, cycling,
nd running) (3,41), and dedicated cycling events (42,43)
ave each been studied.
Several studies have reported no significant post-exercise
Tn elevations (29,44,45), but the majority of data docu-
ent statistically significant cTn increases after exercise
37–39,46,47). Consequently, there is increasing recogni-
ion that mild increases in serum cTn often follow pro-
onged endurance exercise, but for unclear reasons the
revalence and absolute serum concentrations of the cTn
ncreases vary considerably. Possible explanations include
ifferences in the fitness levels of participants, the type or
Figure 2 Forest Plot Showing Event Rate, Sample Size, and 95
Forest plot showing event rate (number of participants showing a positive cardiac
study. Studies are ranked in ascending magnitude of event rate within in each sub
associated 95% CI for the 1,120 research participants are shown in the bottom ro
tion (%) of men in the study sample. Please note: the reference numbers in the fig
sion from Shave et al. (47).uration of exercise, the timing of the post-exercise sample,
he troponin assay used, and the detection limit used to
efine a “positive” cTn. A recent meta-analysis (47) exam-
ned data from 26 studies and found that post-exercise cTn
oncentrations exceeded the assay’s lower limit (i.e., were
easurable) in approximately one-half of participants
Fig. 2). There was a higher incidence of cTnT elevation
fter running events than after cycling or a triathlon.
nterestingly, cTn detection was increasingly common as
uration shortened; specifically, there was a higher inci-
ence of post-exercise cTn in marathon-type events in
ontrast to ultra-marathon competitions. This inverse re-
ationship between event duration and troponin elevation
ight be because shorter races are generally performed at
igher exercise intensities. More recent studies have
rovided important information (Table 1) (48 –53), in-
luding the observation that cTn is increased after
rolonged walking in a nonathletic population and that
he magnitude of increase is related to exercise intensity
nd cardiovascular pathology (48).
Studies examining serum cTn during controlled laboratory-
ased exercise testing are sparse. Recently, 9 highly trained
ale triathletes were studied during participation in a
imulated half-ironman event (1.9-km pool swim, 90-km
ycle ergometry, 21.1-km treadmill run), and cTnT in-
reases were observed in 4 of the athletes (54). Middleton et
l. (2) also reported increases in serum cTnT in all of 9
ell-trained men completing a treadmill marathon (Fig. 3).
ata from this report demonstrate that moderate release of
Tn (range 0.02 to 0.04 g/l) begins as early as 30 min into
for Each Study
in T after exercise), sample size (total), and 95% confidence interval (CI) for each
of studies (cycling, running, triathlon). The overall random-effects event rate and
he plot. *Data that were unavailable. Sex is quantified according to the propor-
late to the original article this figure was reprinted from. Reprinted with permis-% CI
tropon
group
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Exercise and Cardiac Troponins July 13, 2010:169–76ustained endurance exercise and might represent a normal
r “physiologic” response to exercise. This study used
epeated blood draws and was the first to demonstrate cTn
elease in all participants and suggests that the disparate cTn
revalence in previous studies might reflect differences in
tudy design such as the timing of post-exercise blood
raws. More recently, cTnT concentrations have been
ecent Studies Examining Post-Exercise cTn LevelsTable 1 Recent Studies Examining Post-Exercise cTn Levels
Activity
First Author (Ref. #) Distance
Number of
Participants
Trop
M
Walking
Eijsvogels et al. (48) 30–50 km (4 consecutive days) 103
Running
Lippi et al. (45) HM 17
Jassal et al. (49) HM
FM
61 (HM)
68 (FM)
Mingels et al. (36) FM 85
Fortescue et al. (37) FM 482
Mousavi et al. (38) FM 14
Middleton et al. (2) FM 9
Scott et al. (50) 160 km 25
Giannitsis et al. (51) 216 km 10
Cycling
Serrano-Ostariz et al. (52) 206 km 91
Triathlon
La Gerche et al. (53) IM 26
tudies after 2006.
cTn  cardiac troponin; cTnI  cardiac troponin I; cTnT  cardiac troponin T; FM  full mar
re-commercial assay from Roche Diagnostics (Basel, Switzerland); IM  ironman distance (swim
Figure 3 Individual cTnT Release During and After Completion
Individual cardiac troponin T (cTnT) release during (min) and after (h, after exerciseompared in 13 adolescent male runners (age 14.8  1.6
ears) after 4 constant load treadmill runs of varying
uration (45 or 90 min) and intensity (80% or 100%
entilatory threshold) (55). Of note, the highest median
TnT concentration (0.06 g/l, range 0.01 to 0.417 g/l)
as observed after the longest exercise duration (90 min)
nd highest exercise intensity (100% ventilatory threshold).
oform
red
cTn Diagnostic
Threshold Prevalence of Positive cTn Observed
0.01 ug/ml
0.2 ug/ml
18%
6%
0.03 ng/ml 0%
“Detectable” HM: 30.6% immediately after race; 45.9% at 1 h after
FM: 35.7% immediately after race; 52.8% at 1 h after
T 99th percentile
99th percentile
86%
45%
0.01 ng/ml 68%
0.01 ng/ml 100%
0.01 ug/ml 100%
0.01 ug/ml 20%
T 99th percentile 50%
0.04 43%
0.16 ng/ml 58%
(26.2 miles/42.2 km); HM  half marathon (13.1 miles/21.2 km); hs-cTnT  highly sensitive
miles/3.8 km, cycle  112 miles/180 km, run  26.2 miles/42.2 km).
arathon
pletion of a marathon. Reprinted with permission from Middleton et al. (2).onin Is
easu
cTnI
cTnT
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July 13, 2010:169–76 Exercise and Cardiac Troponinslthough these previous findings strongly suggest that
xercise intensity and duration are important determinants
f circulating post-exercise cTn, further laboratory-based
ssessments are needed to clarify this issue.
Tn elevation and myocardial function. A number of
nvestigators have coupled cTn testing with noninvasive
ssessment of cardiac function after endurance events.
ompetitors have been examined minutes to hours after
ace completion (38,56) and in the ensuing weeks (56) to
onths (57). Results from such efforts have been inconsis-
ent. For example, Neilan et al. (4) measured cTnT and
erformed echocardiography 20 min after the race in non-
lite participants completing the Boston Marathon, a
2-km footrace, in an average time of approximately 4 h.
hese authors reported that 63% of participants had a serum
TnT 0.01 g/l, 45% had a serum cTnT 0.03 g/l (the
pper limit of normal), and 13% had cTnT levels in excess
f 0.10 g/l. Increases in cTnT were associated with
eductions in right ventricular contractility, measured by
train echocardiography. However, although concomitant
hanges in cardiac function and cTn release have been
hown after prolonged exercise, correlation analysis does not
rove cause and effect. Furthermore, George et al. (40)
bserved no correlation between post-race troponin eleva-
ions and echocardiographic parameters of left ventricular
unction in a small cohort of athletes completing the
omrades Marathon, an 89-km footrace.
Elevations in cTn and possible impaired myocardial func-
ion raise the question of whether prolonged endurance exer-
ise could produce persistent myocardial damage and dysfunc-
ion. Mousavi et al. (38) reported elevated cTnT in 14
arathon finishers with concomitant echocardiographic evi-
ence of transient right ventricular systolic and biventricular
iastolic dysfunction. Contrast-enhanced magnetic resonance
maging 1 week after the marathon did not show any evidence
f persistent myocardial dysfunction or myocardial fibrosis.
he majority of noninvasive imaging data argue against an
ssociation between post-exercise cTn elevations and perma-
ent myocardial injury (34,58), but a case report of myocardial
brosis in a veteran endurance athlete (59) and a study finding
ncreased late gadolinium enhancement by contrast-enhanced
agnetic resonance imaging in master’s (age 50 to 72 years)
arathoners (60) underscore the need for further work.
otential Mechanisms
f Exercise-Induced cTn Release
everal theories, each presently lacking sufficient confirma-
ory data for full acceptance, have been proposed to explain
Tn elevations after prolonged or strenuous exercise.
ncreased membrane permeability. Exercise-induced in-
reases in myocardial sarcolemmal permeability might facil-
tate the release of cytosolic cTn. Thus, it is possible that
ost-exercise cTn is due to passive diffusion of cTn from the
ntra- to extra-cellular compartment. Such an increase inembrane permeability might be due to increased mechan- acal stress on the cardiomyocytes (61), increased production
f oxidative radicals (62), or altered acid base balance (63).
hese physiologic processes have been documented in
keletal muscle exposed to exercise and seem to play an
mportant role in adaptive skeletal muscle hypertrophy
61,64). Mechanical stimuli might produce transient dis-
uptions of the myocardial plasma membrane, termed “cell
ounds” (65), making it possible that exercise-induced cTn
elease reflects the activation of cellular cascades that result
n cardiac hypertrophy (58).
An alternative mechanism for exercise-induced cTn release
s the stimulation of integrins by myocardial stretch (66).
ntegrins act as bidirectional signaling molecules and are
nvolved in cardiac re-modeling with pressure overload or after
yocardial infarction (67). Stimulating stretch-responsive in-
egrins mediates the transport of intact cTn molecules out of
iable cardiomyocytes (68). This release differs from the dis-
harge of cTnI from necrotic cardiac myocytes, which is
ssociated with extensive cTnI degradation.
After ACS, both intact cTn and degradation products of
Tn are present in the serum (69). Eleven modified cTnI
roducts have been identified, and the number and extent of
odified proteins change with time after the acute event (70).
number of cTnT fragments have also been detected (70). It
s possible that the release of cTn after exercise reflects the
elease of degraded cTn products rather than intact troponin.
ecently, Feng et al. (71) have shown in a rat model the
egradation of cTnI with increasing preload, in the absence of
schemia, suggesting that myocardial stretch per se can degrade
Tn. Although prolonged exercise results in sustained periods
f myocardial stretch, no study has yet examined cTn degra-
ation products after exercise.
yocardial cell necrosis. Myocardial cell necrosis might
lso be responsible for post-exercise cTn elevations. It is
ossible that some individuals with detectable post-exercise
erum cTn will have sustained a myocardial injury with cell
eath. This explanation for post-exercise cTn elevation is not
resently supported by convincing data. In addition, the
elatively small elevations in cTn that have been observed after
xercise and the kinetics recently described (2) do not seem to
upport irreversible cell death. As discussed previously, cTn
elease during ACS follows a biphasic pattern with an initial
elease approximately 2 h after the event followed by a later
elease due to degradation of the contractile apparatus. If exercise-
nduced cTn release were due to cell death of even a small number
f cardiomyocytes, a similar sustained release of cTn would be
nticipated, and there are no data to support this theory. Conse-
uently, it remains unclear what underlies the presence of cTn
fter exercise; however, the data that are available support a
echanism of release that is unrelated to frank myocardial injury.
linical Approach to Patients
ith Post-Exercise cTn Elevation
Tn measurement has a firmly established role in the
ssessment and management of patients with cardiovas-
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Exercise and Cardiac Troponins July 13, 2010:169–76ular disease. Serum cTn elevation is central to the
iagnosis of ACS, and thus clinicians need to be aware of
lternative conditions that might cause cTn elevations.
he data summarized in this review indicate that partic-
pation in endurance-based athletic events can lead to
ild cTn elevation in the absence of ACS. Although the
ubsequent management of patients with post-exercise
Tn elevation remains controversial, some have suggested
hat all athletes presenting with exercise-induced cTn
levations should undergo comprehensive diagnostic
valuation (72). Because it is now clear that cTn release
ight occur routinely after prolonged or strenuous en-
urance exercise in healthy individuals without cardio-
ascular disease, such investigations seem to be unwar-
anted in the majority of cases.
In our opinion, routine cTn testing is not indicated for
he evaluation of individuals who present for medical
ttention after participation in athletic events or substantial
xercise sessions, unless there are specific clinical data
uggesting cardiac involvement. Patients encountered in the
ost-exercise setting should undergo a comprehensive med-
cal history and physical examination with attention directed
o the presence of cardiovascular signs/symptoms and risk
actors for atherosclerostic disease. Twelve-lead electrocar-
iography should be considered as an option in this routine
Figure 4 Algorithm Outlining Proposed Management of Patient
Algorithm for the initiation of cardiac troponin (cTn) testing in patients after prolon
as an adjunct to the standard clinical guidelines for acute coronary syndrome (ACSssessment. Patients found to have common post-
articipation ailments (i.e., musculoskeletal injury, derma-
ologic complaints, dehydration, malnutrition, thermal in-
ury) and no evidence of cardiopulmonary involvement do
ot require an assessment of serum cTn concentration. In
ontrast, it is valuable to measure serum cTn in individ-
als who present with post-exercise complaints that
ight be explained or mediated by myocardial ischemia
uch as chest pain, palpitations, unusual/inappropriate
yspnea, or syncope not clearly attributable to volume
epletion or neurocardiogenic mechanism. In these cir-
umstances, the finding of an elevated cTn coupled with
he moderate to high pre-test probability that cTn
levation reflects more than benign exercise-induced
elease, is sufficient to mandate adherence to published
uidelines for the management of ACS. Such patients
equire hospital admission for observation, serial cTn
easurement, risk-stratification, and/or definitive inter-
ention. An algorithm delineating this proposed ap-
roach has been provided (Fig. 4).
uture Studies
lthough the mechanisms responsible for the release of cTn
fter exercise remain uncertain, a number of plausible,
h Suspected ACS After Prolonged Exercise
ercise, proposed
 electrocardiogram.s Wit
ged ex
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July 13, 2010:169–76 Exercise and Cardiac Troponinserhaps complementary suggestions have been proposed
nd warrant further investigation. The influence of exercise
n cardiac sarcolemmal permeability and integrins both
eserve attention. Furthermore, the study of circulating cTn
ragments after exercise might provide additional insight
nto the mechanisms of release and might also assist in the
ifferentiation of exercise-induced cTn release from patho-
ogical release. Continued study of the influence of a
ifetime of endurance or ultra-endurance exercise upon the
eart is also prudent, given the case reports of myocardial
brosis and late gadolinium enhancement in a small number
f veteran athletes. Finally, more comprehensive reporting
f exercise-related cardiac complications and the role of
linically indicated cTn measurement in this setting are
eeded.
onclusions
Tn testing is an invaluable tool for the assessment of
atients with suspected or confirmed myocardial ischemia/
nfarction. The development of highly specific cTn assays
oupled with theoretical concern about the cardiovascular
afety of prolonged or strenuous exercise has led to numer-
us studies documenting cTn elevation after exercise. Be-
ause most of these data involve healthy individuals with no
nderlying cardiovascular disease, it seems likely that
xercise-induced cTn release is a benign process. Wide-
pread recognition that exercise stimulates release of cTn
ill help physicians to make informed clinical decisions
bout how to use cTn testing appropriately in patients who
resent after exercise.
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